Buy Rating for Charles River Associates Backed by Strong A&CE Performance and Positive Growth Indicators
Charles River Labs Is Maintained at Neutral by Baird
Charles River Analyst Ratings
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Announces Target Price $210
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating
Hold Rating on Charles River Labs Amidst Pharma Restructuring and Uncertain Near-Term Earnings
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating
Charles River Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)
Baird Cuts Charles River Labs to Neutral, Cites Lagging Recovery
Charles River Analyst Ratings
Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $250 From $290
Evercore ISI Group Maintains Outperform on Charles River, Lowers Price Target to $225
Barclays Keeps Their Hold Rating on Charles River Labs (CRL)
Charles River Labs Price Target Cut to $191.00/Share From $239.00 by Baird
Charles River Analyst Ratings
Baird Downgrades Charles River to Neutral, Lowers Price Target to $191
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $240 From $300
Stephens Adjusts Price Target on Charles River Laboratories International to $250 From $280
Baird Adjusts Price Target on Charles River Laboratories International to $239 From $271